fulvestrant + vinorelbine

Fulvestrant + vinorelbine is a combination regimen of two pharmaceutical agents used in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) recurrent or metastatic breast cancer. Fulvestrant is a selective estrogen receptor degrader (SERD) that binds, blocks, and accelerates degradation of the estrogen receptor, thereby inhibiting estrogen signaling in breast cancer cells. Vinorelbine is a semi-synthetic vinca alkaloid chemotherapeutic agent that inhibits microtubule assembly, disrupting mitosis and leading to cell death. The combination has shown synergistic antitumor effects both in vitro and in clinical studies for ER-positive breast cancer, with fulvestrant downregulating chemoresistance factors such as Bcl2 and microtubule-associated protein tau. This dual approach targets both endocrine pathways and proliferative mechanisms to improve outcomes for patients with advanced HR+/HER2− breast cancer[1][2][5].

Other names

fluvestrant + oral vinorelbinefulvestrant + oral vinorelbine